Aptamer Group PlcLSE: APTA

Results of 2025 Annual General Meeting

· Issued by Aptamer Group Plc
Watch Aptamer explain itAPTAMER GROUP PLC (APTA) — Interim Results · Replay · Mar 30
Ask Aptamer's CEO a questionAPTAMER GROUP PLC (APTA) — Full year results for the year ended 30 June 2026 · Oct 13, 2026 at 1:00 PM UTCRegister

27 November 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Results of 2025 Annual General Meeting

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry,  today announces that the results of voting on the resolutions put to shareholders at its Annual General Meeting (AGM) held earlier today at 11:00 am at the offices of Aptamer Group, Windmill House, Innovation Way, York, YO23 1LR, all Resolutions were duly passed.

Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 3 November 2025, and the full poll results will be made available on the Aptamer website later today.

- Ends -

For further information, please contact: 

Aptamer Group plc  

Dr Arron Tolley, Chief Executive Officer

+44 (0) 1904 217 404  

SPARK Advisory Partners Limited - Nominated Adviser    

Andrew Emmott   

+44 (0) 20 3368 3550  

Turner Pope Investments (TPI) Limited - Broker    

Andrew Thacker / Guy McDougall 

+44 (0) 20 3657 0050  

Northstar Communications Limited - Investor Relations

Sarah Hollins 

+44 (0) 113 730 3896

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/